Which is better, leuprolide or degarelix?
Both carry human RCT evidence and FDA approval, and the head-to-head trial met noninferiority for degarelix on castration maintenance. Degarelix is preferable when an immediate, flare free drop in testosterone matters, such as spinal metastases or urinary obstruction where a leuprolide flare could cause harm. Leuprolide is preferable for convenience (3, 4, or 6 month depots versus monthly degarelix injections), tolerability at the injection site, and non-prostate indications such as endometriosis, fibroids, and central precocious puberty. [1] [2] [4] [5]
How do leuprolide and degarelix compare?
| Dimension | Leuprolide | Degarelix |
|---|---|---|
| Mechanism [1] [4] [5] | GnRH receptor agonist: first stimulates then downregulates pituitary receptors, causing a 1 to 2 week testosterone flare before suppression. | GnRH receptor antagonist: blocks the receptor immediately, with no initial surge and no microsurges on repeat dosing. |
| Speed of testosterone suppression [1] | 0% castrate by day 3; median testosterone rose about 65% in the first week before falling. | 96% castrate by day 3, with a faster PSA decline. |
| Castration maintenance at 1 year [1] | 96.4% with testosterone at or below 0.5 ng/mL from day 28 to day 364 (7.5 mg monthly). | 97.2% (240/80 mg) and 98.3% (240/160 mg), meeting noninferiority. |
| Dosing interval [4] [5] | Depots every 1, 3, 4, or 6 months (Lupron Depot 7.5, 22.5, 30, or 45 mg; Eligard, Camcevi). | 240 mg loading dose as two injections, then 80 mg every 28 days. |
| Injection site reactions [1] [4] | Under 1% in the head-to-head trial; occasional sterile abscess with intramuscular depot. | About 40%, mostly pain, redness, swelling, or nodules after the loading dose. |
| FDA indications [4] [5] | Advanced prostate cancer (since 1985), endometriosis, uterine fibroids, and central precocious puberty; generic available. | Advanced prostate cancer only (Firmagon, December 2008); no generic. |
| Survival evidence [1] [2] [3] | Matched diethylstilbestrol for response and 1 year survival with fewer cardiovascular side effects; adding flutamide extended median survival from 28.3 to 35.6 months. | No survival trial; approval based on testosterone suppression versus leuprolide. A lower cardiovascular event rate in men with heart disease has been suggested in pooled analyses but not confirmed. |
| WADA status [6] | Prohibited in males under S2 as a GnRH analog. | Not prohibited. |
| Typical cost [4] [5] | Lupron Depot 7.5 mg roughly 2,000 to 2,500 USD per monthly injection at list; Eligard and generics lower. | Roughly 600 to 900 USD per monthly 80 mg injection at list; the loading dose costs about twice that. |
| Note: Both are usually covered by Medicare Part B and commercial insurance for prostate cancer. | ||
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | Leuprolide | Degarelix |
|---|---|---|
| Class | Synthetic nonapeptide GnRH (LHRH) agonist analog | Synthetic decapeptide GnRH (LHRH) receptor antagonist |
| What it is | FDA approved since 1985; after a brief surge it shuts down testosterone or estrogen; standard therapy for prostate cancer, endometriosis, and early puberty. | FDA approved GnRH blocker for advanced prostate cancer: castrate testosterone in 3 days with no flare, held in 97 to 98% at 1 year in a 610 patient trial. |
| Evidence | Evidence: Human RCT evidence | Evidence: Human RCT evidence |
| FDA status | Regulatory: FDA approved | Regulatory: FDA approved |
| Compounding | FDA approved as Lupron injection in April 1985 for advanced prostate cancer, with Lupron Depot (1989), Lupron Depot-Ped (1993), Eligard (2002), Fensolvi (2020), and Camcevi (2021) following for prostate cancer, endometriosis, fibroids, and central precocious puberty. Generic leuprolide injection is available. Compounding is limited to patient specific needs because approved products exist. | FDA approved as Firmagon in December 2008 for advanced prostate cancer. No generic is available as of the last verified date. Because an approved product exists, compounding is not permitted beyond patient specific exceptions. |
| WADA | WADA: WADA prohibited | WADA: Not WADA prohibited |
| Routes | Intramuscular depot every 1, 3, 4, or 6 months (Lupron Depot), Subcutaneous depot every 1 to 6 months (Eligard, Fensolvi, Camcevi), Subcutaneous injection once daily (leuprolide acetate 1 mg) | Subcutaneous injection into the abdomen every 28 days (loading dose given as two injections) |
| Typical cost | Lupron Depot 7.5 mg lists at roughly 2,000 to 2,500 USD per monthly injection and about 6,000 to 7,000 USD for the 3 month 22.5 mg depot; Eligard and generic leuprolide are lower. Insurance and Medicare Part B routinely cover it for cancer and other approved indications. | Roughly 600 to 900 USD per monthly 80 mg maintenance injection at list price, with the 240 mg loading dose about twice that. Insurance and Medicare Part B cover it for prostate cancer. |
| Last verified |
Has leuprolide been tested directly against degarelix?
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer2008 PMID 19035858 | Randomized, open label, active comparator noninferiority trial, 12 monthsn = 610 Men with prostate cancer of any stage requiring androgen deprivation therapy | Testosterone 0.5 ng/mL or below from day 28 to 364 in 97.2% (degarelix 240/80 mg) and 98.3% (240/160 mg) versus 96.4% with leuprolide 7.5 mg; castration by day 3 in 96% versus 0%; injection site reactions about 40% versus under 1% | Evidence: Human RCT evidence |
What do leuprolide and degarelix cost?
| Dimension | Leuprolide | Degarelix |
|---|---|---|
| Typical cost | Lupron Depot 7.5 mg lists at roughly 2,000 to 2,500 USD per monthly injection and about 6,000 to 7,000 USD for the 3 month 22.5 mg depot; Eligard and generic leuprolide are lower. Insurance and Medicare Part B routinely cover it for cancer and other approved indications. | Roughly 600 to 900 USD per monthly 80 mg maintenance injection at list price, with the 240 mg loading dose about twice that. Insurance and Medicare Part B cover it for prostate cancer. |
| Price detail | Price index in progress | Price index in progress |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Frequently asked questions
Is degarelix better than leuprolide for prostate cancer?
At 1 year they suppress testosterone equally well (97.2% to 98.3% versus 96.4% in the direct trial). Degarelix gets there much faster, castrate by day 3 in 96% of men versus none on leuprolide, and avoids the flare. Leuprolide needs fewer injections and causes far fewer injection site reactions. [1]
What is the testosterone flare and why does it matter?
Leuprolide initially stimulates the pituitary, so testosterone rises for 1 to 2 weeks before falling; in the head-to-head trial median testosterone rose about 65% in week 1. In men with spinal metastases or urinary obstruction, that surge can worsen bone pain or cause compression, which is why an antiandrogen is often added or an antagonist such as degarelix is used. [1] [4]
How often are the injections?
Degarelix is given every 28 days after a two injection loading dose. Leuprolide depots can be given every 1, 3, 4, or 6 months depending on the product and dose. [4] [5]
Can either be used for conditions other than prostate cancer?
Leuprolide can: it is approved for endometriosis, uterine fibroids, and central precocious puberty as well. Degarelix is approved only for advanced prostate cancer and is not indicated for women. [4] [5]
Are they prohibited for athletes?
Leuprolide is prohibited in male athletes under WADA section S2 as a GnRH analog. Degarelix, an antagonist that lowers testosterone, is not on the list. [6]
Conditions studied
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Klotz L et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008PubMed 19035858, 2008
- [2]The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984PubMed 6436700, 1984
- [3]Crawford ED et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989PubMed 2503724, 1989
- [4]FDA prescribing information for Lupron Depot (leuprolide acetate) injection, via DailyMedFDA
- [5]FDA prescribing information for Firmagon (degarelix) injection, via DailyMedFDA
- [6]WADA Prohibited List, section S2 (GnRH and its analogs in males)WADA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). Leuprolide vs degarelix: evidence, cost, and legality. https://peptideagent.ai/compare/leuprolide-vs-degarelix- HTML link
<a href="https://peptideagent.ai/compare/leuprolide-vs-degarelix">Leuprolide vs degarelix: evidence, cost, and legality</a>, PeptideAgent, updated September 22, 2026.